Also trades as: INDV.L (LSE) · $vol 5M
INDV NASDAQ
Indivior Pharmaceuticals Inc
1W: +2.0%
1M: -3.5%
3M: -15.7%
YTD: -3.3%
1Y: +36.7%
3Y: +79.1%
5Y: +117.4%
$34.72
+0.16 (+0.46%)
After Hours: $36.79 (+2.07, +5.96%)
Weekly Expected Move ±4.8%
$31
$33
$34
$36
$38
Credit Risk of going bust: lower than 74% of companies Debt: 10.6% of company value Bonds: $90.4M held by 58 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.31 (down 99.1%), Indivior Pharmaceuticals Inc would be worth roughly what it owes.
Total debt $509.0M against a stock market value of $4.31B.
Distance to default 8.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $252.5M (short-term plus half of long-term), stock volatility 36.3%; Altman Z 3.48. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.31 (down 99.1%), Indivior Pharmaceuticals Inc would be worth roughly what it owes.
Total debt $509.0M against a stock market value of $4.31B.
Distance to default 8.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $252.5M (short-term plus half of long-term), stock volatility 36.3%; Altman Z 3.48. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
MSG Rangers and Huron Consulting Group to join S&P SmallCap 600
1,999,416 Indivior PLC $INDV Shares Acquired by Assenagon Asset Management S.A.
Indivior PLC $INDV Stock Bought by Artemis Investment Management LLP
These healthcare stocks stand out with A+ growth grades
Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock
Indivior declares $8.13 dividend
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV
AXQ Capital LP Makes New $959,000 Investment in Indivior PLC $INDV
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Why Indivior Pharmaceuticals Inc. (INDV) is a Top Growth Stock for the Long-Term
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Handelsbanken Fonder AB Takes $1.86 Million Position in Indivior PLC $INDV
Here's Why Indivior Pharmaceuticals Inc. (INDV) is a Strong Growth Stock
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and more
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Why Supernus Pharmaceuticals Stock Topped the Market Today
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Bull of the Day: Neurocrine Biosciences (NBIX)
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Reasons Why Investors Should Consider Betting on Indivior Stock
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
AGIO Stock Surges 35% in Six Months: What's Driving It?
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Is Indivior Stock a Buy After Higher 2026 Guidance?
INDV Stock: What Sublocade Growth Signals for 2026
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
Recent Price Trend in Indivior Pharmaceuticals Inc. (INDV) is Your Friend, Here's Why
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
Here's Why Investors Continue to Hold Ensign Group Stock
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
CORT Stock Rises 42% in a Month: Here's What You Should Know
Here's Why Investors Should Hold on to Teladoc Health Stock for Now
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Zacks.com featured highlights include Indivior, ReNew Energy, Lifetime, NetScout and TEEKAY
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
What to Know About This Fund's $74.8 Million Indivior Sale
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication
Is Molina Healthcare Worth Buying at a Premium 26.83X P/E Valuation?